These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20184089)

  • 1. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
    Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
    J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study.
    Hafer A; Krämer S; Duncker S; Krüger M; Manns MP; Bischoff SC
    BMC Gastroenterol; 2007 Sep; 7():36. PubMed ID: 17784949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
    Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
    Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME; Werida RH; Radwan MA; Askar SR; Omran GA; El-Mohamdy MA; Hagag RS
    Inflammopharmacology; 2024 Oct; 32(5):3259-3269. PubMed ID: 38985232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for the treatment of ulcerative colitis.
    Eshuis EJ; Bemelman WA; Stokkers PC
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.